PortalPublikationenBlood- and tissue-based biomarkers for prediction of outcome...

Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder

Standard

Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. / Xylinas, Evanguelos; Kluth, Luis A; Lotan, Yair; Daneshmand, Siamak; Rieken, Malte; Karakiewicz, Pierre I; Shariat, Shahrokh F.

in: UROL ONCOL-SEMIN ORI, Jahrgang 32, Nr. 3, 01.04.2014, S. 230-242.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Xylinas, E, Kluth, LA, Lotan, Y, Daneshmand, S, Rieken, M, Karakiewicz, PI & Shariat, SF 2014, 'Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder', UROL ONCOL-SEMIN ORI, Jg. 32, Nr. 3, S. 230-242. https://doi.org/10.1016/j.urolonc.2013.06.009

APA

Xylinas, E., Kluth, L. A., Lotan, Y., Daneshmand, S., Rieken, M., Karakiewicz, P. I., & Shariat, S. F. (2014). Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. UROL ONCOL-SEMIN ORI, 32(3), 230-242. https://doi.org/10.1016/j.urolonc.2013.06.009

Vancouver

Xylinas E, Kluth LA, Lotan Y, Daneshmand S, Rieken M, Karakiewicz PI et al. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. UROL ONCOL-SEMIN ORI. 2014 Apr 1;32(3):230-242. https://doi.org/10.1016/j.urolonc.2013.06.009

Bibtex

@article{f412914b6e1d453ca29755cf778c2ceb,
title = "Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder",
abstract = "OBJECTIVES: Urothelial carcinoma of the bladder (UCB) is a highly heterogeneous malignancy that causes significant morbidity and mortality. Standard pathologic features (stage, grade, and nodal status) are insufficient to predict accurately a patient's outcome. Biomarkers could help clinicians provide individualized prognostications and allow risk-stratified clinical decision making regarding surgical and medical treatment. This review summarizes the existing tissue- and blood-based biomarkers in UCB.MATERIAL AND METHODS: A PubMed/Medline search was conducted to identify original articles regarding molecular biomarkers and UCB. Searches were limited to papers published in English. Keywords included urothelial carcinoma, bladder cancer, transitional cell, biomarker, marker, staining, cystectomy, recurrence or progression, survival, prediction, and prognosis.RESULTS: The articles with the highest level of evidence were selected and reviewed, with the consensus of all the authors of this paper.CONCLUSIONS: There is no doubt that a panel of biomarkers would eventually improve our clinical decision making regarding treatment and follow-up. However, to date, no biomarker panel is yet validated for daily clinical practice.",
author = "Evanguelos Xylinas and Kluth, {Luis A} and Yair Lotan and Siamak Daneshmand and Malte Rieken and Karakiewicz, {Pierre I} and Shariat, {Shahrokh F}",
note = "Copyright {\textcopyright} 2014 Elsevier Inc. All rights reserved.",
year = "2014",
month = apr,
day = "1",
doi = "10.1016/j.urolonc.2013.06.009",
language = "English",
volume = "32",
pages = "230--242",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder

AU - Xylinas, Evanguelos

AU - Kluth, Luis A

AU - Lotan, Yair

AU - Daneshmand, Siamak

AU - Rieken, Malte

AU - Karakiewicz, Pierre I

AU - Shariat, Shahrokh F

N1 - Copyright © 2014 Elsevier Inc. All rights reserved.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - OBJECTIVES: Urothelial carcinoma of the bladder (UCB) is a highly heterogeneous malignancy that causes significant morbidity and mortality. Standard pathologic features (stage, grade, and nodal status) are insufficient to predict accurately a patient's outcome. Biomarkers could help clinicians provide individualized prognostications and allow risk-stratified clinical decision making regarding surgical and medical treatment. This review summarizes the existing tissue- and blood-based biomarkers in UCB.MATERIAL AND METHODS: A PubMed/Medline search was conducted to identify original articles regarding molecular biomarkers and UCB. Searches were limited to papers published in English. Keywords included urothelial carcinoma, bladder cancer, transitional cell, biomarker, marker, staining, cystectomy, recurrence or progression, survival, prediction, and prognosis.RESULTS: The articles with the highest level of evidence were selected and reviewed, with the consensus of all the authors of this paper.CONCLUSIONS: There is no doubt that a panel of biomarkers would eventually improve our clinical decision making regarding treatment and follow-up. However, to date, no biomarker panel is yet validated for daily clinical practice.

AB - OBJECTIVES: Urothelial carcinoma of the bladder (UCB) is a highly heterogeneous malignancy that causes significant morbidity and mortality. Standard pathologic features (stage, grade, and nodal status) are insufficient to predict accurately a patient's outcome. Biomarkers could help clinicians provide individualized prognostications and allow risk-stratified clinical decision making regarding surgical and medical treatment. This review summarizes the existing tissue- and blood-based biomarkers in UCB.MATERIAL AND METHODS: A PubMed/Medline search was conducted to identify original articles regarding molecular biomarkers and UCB. Searches were limited to papers published in English. Keywords included urothelial carcinoma, bladder cancer, transitional cell, biomarker, marker, staining, cystectomy, recurrence or progression, survival, prediction, and prognosis.RESULTS: The articles with the highest level of evidence were selected and reviewed, with the consensus of all the authors of this paper.CONCLUSIONS: There is no doubt that a panel of biomarkers would eventually improve our clinical decision making regarding treatment and follow-up. However, to date, no biomarker panel is yet validated for daily clinical practice.

U2 - 10.1016/j.urolonc.2013.06.009

DO - 10.1016/j.urolonc.2013.06.009

M3 - SCORING: Journal article

C2 - 24332648

VL - 32

SP - 230

EP - 242

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 3

ER -